Bristol Myers Squibb Receives European Commission Approval of Zeposia (Ozanimod) for use in Adults with Moderately to Severely Active Ulcerative Colitis

Bristol Myers Squibb announced the European Commission has granted a Marketing Authorization for Zeposia for the treatment of adults with moderately to severely active ulcerative colitis who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.